Drug Detail:Mosunetuzumab (Mosunetuzumab [ moe-sun-e-tooz-ue-mab ])
Drug Class: Miscellaneous antineoplastics
Mosunetuzumab Levels and Effects while Breastfeeding
Summary of Use during Lactation
No information is available on the clinical use of mosunetuzumab during breastfeeding. Because mosunetuzumab is a large protein molecule with a molecular weight of 146,000 Da, the amount in milk is likely to be very low. It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal. The manufacturer recommends that breastfeeding be discontinued during mosunetuzumab therapy and for 3 months after the last dose.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
Mosunetuzumab
CAS Registry Number
1905409-39-3
Drug Class
Breast Feeding
Lactation
Milk, Human
Monoclonal Antibodies, Humanized
Antineoplastic Agents
-
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- Drug Levels and Effects
- Substance Identification